Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
List view / Grid view
Filter the results
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.